Stromal matrix protein expression following preoperative systemic therapy in breast cancer

A. Tőkés, A. Szász, Andrea Farkas, Adrienn Lldiko Toth, Magdolna Dank, Laszlo Harsanyi, B. Molnár, Istvan Arthur Molnar, Zsolt Laszlo, Zoltan Rusz, J. Kulka

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Stromal alterations are observed following preoperative systemic therapy in breast cancer. The aim of the present study was to analyze the qualitative and quantitative changes of representative tumor stroma proteins in the context of neoadjuvant therapy and the response of patients undergoing preoperative systemic therapy. Experimental Design: Fifty women receiving preoperative systemic therapy were evaluated for clinical and pathologic parameters. Clinical response was defined according to International Union against Cancer (UICC) criteria, whereas pathologic responses to preoperative systemic therapy were defined according to the Chevallier and Sataloff classifications. The expression of tenascin-C, syndecan-1, collagen IV, and smooth muscle actin proteins was investigated using morphometric analysis of immunohistochemical reactions. Quantitative reverse transcription -PCR was done to evaluate the mRNA expression level of syndecan-1 and tenascin-C. The data were compared with 20 breast cancer samples of patients not treated with preoperative systemic therapy. Results: According to UICC criteria, the expression levels of collagen IV were up-regulated in all preoperative systemic therapy - treated patients (P = 0.002). Collagen IV was up-regulated in the preoperative systemic therapy group in both Chevallier and Sataloff classifications compared with the control cases (P = 0.025 and P = 001, respectively). There were no significant differences in the expression of smooth muscle actin between the treated and nontreated groups. The syndecan-1 proteoglycan level was significantly down-regulated in the preoperative systemic therapy group (Chevallier classes P = 0.015, Sataloff classes P = 0.015). Tenascin-C was up-regulated in women with progressive disease (P = 0.005). Conclusion: We have observed that the stromal component of breast carcinomas following preoperative systemic therapy differs from the nontreated tumors, which can be evaluated with the analysis of the above mentioned proteins.

Original languageEnglish
Pages (from-to)731-739
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number2
DOIs
Publication statusPublished - Jan 15 2009

Fingerprint

Breast Neoplasms
Syndecan-1
Tenascin
Proteins
Collagen
Group Psychotherapy
Therapeutics
Smooth Muscle
Actins
Neoplasms
Neoadjuvant Therapy
Muscle Proteins
Proteoglycans
Reverse Transcription
Research Design
Polymerase Chain Reaction
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stromal matrix protein expression following preoperative systemic therapy in breast cancer. / Tőkés, A.; Szász, A.; Farkas, Andrea; Toth, Adrienn Lldiko; Dank, Magdolna; Harsanyi, Laszlo; Molnár, B.; Molnar, Istvan Arthur; Laszlo, Zsolt; Rusz, Zoltan; Kulka, J.

In: Clinical Cancer Research, Vol. 15, No. 2, 15.01.2009, p. 731-739.

Research output: Contribution to journalArticle

Tőkés, A. ; Szász, A. ; Farkas, Andrea ; Toth, Adrienn Lldiko ; Dank, Magdolna ; Harsanyi, Laszlo ; Molnár, B. ; Molnar, Istvan Arthur ; Laszlo, Zsolt ; Rusz, Zoltan ; Kulka, J. / Stromal matrix protein expression following preoperative systemic therapy in breast cancer. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 2. pp. 731-739.
@article{32abc71ea4a34844b5dbbe0a1f38246b,
title = "Stromal matrix protein expression following preoperative systemic therapy in breast cancer",
abstract = "Purpose: Stromal alterations are observed following preoperative systemic therapy in breast cancer. The aim of the present study was to analyze the qualitative and quantitative changes of representative tumor stroma proteins in the context of neoadjuvant therapy and the response of patients undergoing preoperative systemic therapy. Experimental Design: Fifty women receiving preoperative systemic therapy were evaluated for clinical and pathologic parameters. Clinical response was defined according to International Union against Cancer (UICC) criteria, whereas pathologic responses to preoperative systemic therapy were defined according to the Chevallier and Sataloff classifications. The expression of tenascin-C, syndecan-1, collagen IV, and smooth muscle actin proteins was investigated using morphometric analysis of immunohistochemical reactions. Quantitative reverse transcription -PCR was done to evaluate the mRNA expression level of syndecan-1 and tenascin-C. The data were compared with 20 breast cancer samples of patients not treated with preoperative systemic therapy. Results: According to UICC criteria, the expression levels of collagen IV were up-regulated in all preoperative systemic therapy - treated patients (P = 0.002). Collagen IV was up-regulated in the preoperative systemic therapy group in both Chevallier and Sataloff classifications compared with the control cases (P = 0.025 and P = 001, respectively). There were no significant differences in the expression of smooth muscle actin between the treated and nontreated groups. The syndecan-1 proteoglycan level was significantly down-regulated in the preoperative systemic therapy group (Chevallier classes P = 0.015, Sataloff classes P = 0.015). Tenascin-C was up-regulated in women with progressive disease (P = 0.005). Conclusion: We have observed that the stromal component of breast carcinomas following preoperative systemic therapy differs from the nontreated tumors, which can be evaluated with the analysis of the above mentioned proteins.",
author = "A. Tők{\'e}s and A. Sz{\'a}sz and Andrea Farkas and Toth, {Adrienn Lldiko} and Magdolna Dank and Laszlo Harsanyi and B. Moln{\'a}r and Molnar, {Istvan Arthur} and Zsolt Laszlo and Zoltan Rusz and J. Kulka",
year = "2009",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1523",
language = "English",
volume = "15",
pages = "731--739",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Stromal matrix protein expression following preoperative systemic therapy in breast cancer

AU - Tőkés, A.

AU - Szász, A.

AU - Farkas, Andrea

AU - Toth, Adrienn Lldiko

AU - Dank, Magdolna

AU - Harsanyi, Laszlo

AU - Molnár, B.

AU - Molnar, Istvan Arthur

AU - Laszlo, Zsolt

AU - Rusz, Zoltan

AU - Kulka, J.

PY - 2009/1/15

Y1 - 2009/1/15

N2 - Purpose: Stromal alterations are observed following preoperative systemic therapy in breast cancer. The aim of the present study was to analyze the qualitative and quantitative changes of representative tumor stroma proteins in the context of neoadjuvant therapy and the response of patients undergoing preoperative systemic therapy. Experimental Design: Fifty women receiving preoperative systemic therapy were evaluated for clinical and pathologic parameters. Clinical response was defined according to International Union against Cancer (UICC) criteria, whereas pathologic responses to preoperative systemic therapy were defined according to the Chevallier and Sataloff classifications. The expression of tenascin-C, syndecan-1, collagen IV, and smooth muscle actin proteins was investigated using morphometric analysis of immunohistochemical reactions. Quantitative reverse transcription -PCR was done to evaluate the mRNA expression level of syndecan-1 and tenascin-C. The data were compared with 20 breast cancer samples of patients not treated with preoperative systemic therapy. Results: According to UICC criteria, the expression levels of collagen IV were up-regulated in all preoperative systemic therapy - treated patients (P = 0.002). Collagen IV was up-regulated in the preoperative systemic therapy group in both Chevallier and Sataloff classifications compared with the control cases (P = 0.025 and P = 001, respectively). There were no significant differences in the expression of smooth muscle actin between the treated and nontreated groups. The syndecan-1 proteoglycan level was significantly down-regulated in the preoperative systemic therapy group (Chevallier classes P = 0.015, Sataloff classes P = 0.015). Tenascin-C was up-regulated in women with progressive disease (P = 0.005). Conclusion: We have observed that the stromal component of breast carcinomas following preoperative systemic therapy differs from the nontreated tumors, which can be evaluated with the analysis of the above mentioned proteins.

AB - Purpose: Stromal alterations are observed following preoperative systemic therapy in breast cancer. The aim of the present study was to analyze the qualitative and quantitative changes of representative tumor stroma proteins in the context of neoadjuvant therapy and the response of patients undergoing preoperative systemic therapy. Experimental Design: Fifty women receiving preoperative systemic therapy were evaluated for clinical and pathologic parameters. Clinical response was defined according to International Union against Cancer (UICC) criteria, whereas pathologic responses to preoperative systemic therapy were defined according to the Chevallier and Sataloff classifications. The expression of tenascin-C, syndecan-1, collagen IV, and smooth muscle actin proteins was investigated using morphometric analysis of immunohistochemical reactions. Quantitative reverse transcription -PCR was done to evaluate the mRNA expression level of syndecan-1 and tenascin-C. The data were compared with 20 breast cancer samples of patients not treated with preoperative systemic therapy. Results: According to UICC criteria, the expression levels of collagen IV were up-regulated in all preoperative systemic therapy - treated patients (P = 0.002). Collagen IV was up-regulated in the preoperative systemic therapy group in both Chevallier and Sataloff classifications compared with the control cases (P = 0.025 and P = 001, respectively). There were no significant differences in the expression of smooth muscle actin between the treated and nontreated groups. The syndecan-1 proteoglycan level was significantly down-regulated in the preoperative systemic therapy group (Chevallier classes P = 0.015, Sataloff classes P = 0.015). Tenascin-C was up-regulated in women with progressive disease (P = 0.005). Conclusion: We have observed that the stromal component of breast carcinomas following preoperative systemic therapy differs from the nontreated tumors, which can be evaluated with the analysis of the above mentioned proteins.

UR - http://www.scopus.com/inward/record.url?scp=59449093811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449093811&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1523

DO - 10.1158/1078-0432.CCR-08-1523

M3 - Article

C2 - 19147781

AN - SCOPUS:59449093811

VL - 15

SP - 731

EP - 739

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -